$Moderna(MRNA.US) Post some recent information. Psychological massage?

Moderna's RSV vaccine approved

On June 12, 2025, Moderna received FDA approval to expand its RSV vaccine mRESVIA® to high-risk adults aged 18-59. Previously, the vaccine was approved in May 2024 for people over 60. This indicates that mRNA technology is expanding in the field of respiratory diseases and is expected to be available during the 2025-2026 respiratory virus season.

Phase 3 clinical trial products

Moderna's main products currently in Phase 3 clinical trials include the following, showing its R&D focus:

- Influenza vaccine:

- mRNA-1010, for adults aged 65 and older, announced positive Phase 3 results in September 2024 compared to high-dose licensed comparators, planned to submit for regulatory approval in 2025, but the accelerated approval plan has been canceled, shifting focus to combination vaccines.

- Combination vaccine:

- mRNA-1083 (influenza + COVID-19 combination vaccine), in Phase 3, aims to provide seasonal prevention convenience, expected to submit for approval in 2025, using a priority review voucher to accelerate the process.

- Latent virus vaccines:

- mRNA-1647 (cytomegalovirus CMV vaccine), in Phase 3, targeting high-risk groups for potential infection, such as pregnant women and immunocompromised patients.

- mRNA-1403 (norovirus vaccine), in Phase 3, targeting intestinal virus infection, with positive progress mentioned at the J.P. Morgan conference in January 2025.

- Cancer treatment:

- mRNA-4157 (Intismeran autogene), in collaboration with Merck, for adjuvant treatment of melanoma and non-small cell lung cancer (NSCLC), including postoperative adjuvant and preoperative neoadjuvant therapy, all in Phase 3, expected to commercialize in Q2 2027.